Epidemiologisches Bulletin ; 12. Dezember 2016 / Nr. 49 aktuelle daten und informationen zu infektionskrankheiten und public health
Презентация на тему «Остановим туберкулез»
Accessed on 2019
WHO Regional EVD Preparedness Meeting Presentations January 14-16, 2015
A case study from Bosnia and Herzegovina Eurasian Harm Reduction Network
The case study was prepared by Samir Ibisevic, President of PROI between March and June 2016 and edited by Graham Shaw.
EHRN is grateful to all who contributed to this document, especially: Dr. Serifa Godinjak, Chairperson... of Country Coordinating Mechanism; Dr. Zlatko Cardaklija, HIV Coordinator for the Federation of Bosnia and Herzegovina (BiH); Dr. Nesad Seremet, Head of the HIV program, United Nations Development Program in Bosnia and Herzegovina; Ms. Gyongyver Jakab, Fund Portfolio Manager, Eastern Europe and Central Asia and Ms. Natalya Bogach, Program Officer, The Global Fund to Fight AIDS, Tuberculosis and Malaria; Dr. Nermana Mehic–Basara, Director of the Institute for Addiction Diseases of Sarajevo Canton; Mr. Denis Dedajic, Director of the Association Margina from the Federation of BiH; Mr. Srdjan Kukolj, Director of Action Against AIDS from the Republic of Srpska.
more
Руководство по инвестициям Глобального фонда для стран Восточной Европы и Центральной Азии. В ходе разработки Руководства Глобальный фонд стремился учесть мнени... всех значимых участников борьбы с эпидемиями ВИЧ-инфекции и туберкулеза в Восточной Европе и Центральной Азии и с этой целью провел ряд консультаций и рабочих встреч с широким кругом заинтересованных сторон, на которых обсуждались цели и принципы дифференцированного подхода к противодействию эпидемиям в регионе, а также механизмы реализации этих целей и принципов.
Accessed on 2019
more
ACAPS Briefing Note: Zika virus epidemic
Review
Journal of Virus Eradication 2016 Jul; 2(3): 156–161.
Published online 2016 Jul 1.
PMCID: PMC4967967
PMID: 27482455
"NUR" CYPU
Accessed: 26.09.2019
Eine Stellungnahme des DZK in Zusammenarbeit mit FZB, DGI, DGPI, GPP, DGGG, DRG und DGMP
Pneumologie 2016; 70: 777–780
The extensive use of antimicrobials in human and veterinary medicine in recent years has accelerated the emergence and spread of resistant microorganisms. This situation has been worsened by the lack of investment in developing new effective antibiotics. The severity of the consequences is clear to ...see: it is estimated that each year, drug-resistant infections result in at least 25 000 patient deaths and cost the EU EUR 1,5 billion in healthcare costs and through loss of productivity
more
Carbapenems are a major last-line class of antibiotics to treat bacterial infections.The spread of carbapenem-resistant infections is a threat to healthcare andpatient safety in Europe as it seriously curtails the ability to cure infections. The spread of carbapenem-resistant infections is a threat ...to healthcare and patient safety in Europe as it seriously curtails the ability to cure infections.
more
Antibiotic resistance is a natural occurrence caused by mutations in bacteria’s genes. However, inappropriate use of antibiotics accelerates the emergence and spread of antibiotic-resistant bacteria. When exposed to antibiotics, susceptible bacteria are killed; while excessive antibiotic use or th...eir use for the wrong reasons can cause bacteria to become resistant and continue to grow and multiply. These resistant bacteria may spread and cause infections in other people.
more
The ability of bacteria to resist the action of an antibiotic has become a recognised global problem. Antibiotic resistance severely limits the number of antibiotics available for the treatment of diseases.
The Transatlantic Task Force on Antimicrobial Resistance (TATFAR) fosters cooperation between the European Union (EU) andthe United States (US) on the issue of antimicrobial resistance. The first TATFAR recommendation refers to appropriate use of antimicrobials in human medicine through hospital Ant...imicrobial Stewardship Programs (ASPs) and, specifically, to the development of common structure and process indicators of ASP. These indicators should allow characterization of programs and comparisons among healthcare systems in EU and US.
more
Обновленная версия Декабрь 2020 г.